


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-33. (Canceled)

34. (Currently Amended) A method according to claim 26 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds having the general formula II:



wherein


R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF₃, OR18, SR18, OC₁₋₆ alkyl, OC₂₋₆ alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R18, C₁₋₆ alkylCO₂R18, CONR18R19, C₁₋₆ alkylCONR18R19, NR18R19, C₁₋₆ alkylNR18R19, NR20C₁₋₆ alkylNR18R19, C₁₋₆ alkylNR20C₁₋₆ alkylNR18R19, NR18COR19, C₁₋₆ alkylNR18COR19, C₁₋₆ alkylNR20CONR18R19, NR20CONR18R19, C₁₋₆ alkylNR18SO₂R19, NR18SO₂R19; R18, R19 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C₁₋₄alkyl;

R11, R12 are each independently selected from H, C₁₋₄ alkyl, halogen, OC₁₋₄ alkyl;

and wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

35. (Currently Amended) A method according to claim 27 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H, C₁₋₄ alkyl, OC₁₋₄ alkyl, CO₂H, CN;

R11, R12 are each independently selected from H, C₁₋₄ alkyl;

R9 is independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF₃, OR18, SR18, OC₁₋₆ alkyl, OC₂₋₆ alky1NR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R18, C₁₋₆ alkylCO₂R18, CONR18R19, C₁₋₆ alkylCONR18R19, NR18R19, C₁₋₆ alkylNR18R19, NR20C₁₋₆ alkylNR18R19, C₁₋₆ alky1NR20C₁₋₆ alkylNR18R19, NR18COR19, C₁₋₆ alkylNR18COR19, C₁₋₆ alky1NR20CONR18R19, NR20CONR18R19, C₁₋₆ alky1NR18SO₂R19, NR18SO₂R19;

R18, R19 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O,

S, NR21;

R20, R21 are each independently selected from H, C₁₋₄alkyl;


wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

36. (Cancelled)

37. (Cancelled)

38. (Currently Amended) A method according to claim 30 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions comprising:

(a) one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF₃, OR18, SR18, OC₁₋₆ alkyl, OC₂₋₆ alky1NR18R19, Oaryl, Oheteroaryl, Ocy cloalkyl, Ocy cloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R18, C₁₋₆ alkylCO₂R18, CONR18R19, C₁₋₆ alkylCONR18R19, NR18R19, C₁₋₆ alkylNR18R19, NR20C₁₋₆ alkylNR18R19, C₁₋₆ alkylNR20C₁₋₆ alkylNR18R19, NR18COR19, C₁₋₆ alkylNR18COR19, C₁₋₆ alkylNR20CONR18R19, NR20CONR18R19, C₁₋₆ alkylNR18SO₂R19, NR18SO₂R19;

R18, R19 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an

optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C₁₋₄alkyl;


R11, R12 are each independently selected from H, C₁₋₄ alkyl, halogen, OC₁₋₄ alkyl;

(b) a pharmaceutically acceptable diluent,

wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

39. (Currently Amended) A method ~~according to claim 31 for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions comprising:~~

(a) one or more compounds having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H, C₁₋₄ alkyl, OC₁₋₄ alkyl, CO₂H, CN;

R11, R12 are each independently selected from H, C₁₋₄ alkyl;

R9 is independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF₃, OR18, SR18, OC₁₋₆ alkyl, OC₂₋₆ alkylnNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R18, C₁₋₆ alkylCO₂R18, CONR18R19, C₁₋₆ alkylCONR18R19, NR18R19, C₁₋₆ alkylNR18R19, NR20C₁₋₆ alkylNR18R19, C₁₋₆ alkylNR20C₁₋₆ alkylNR18R19, NR18COR19, C₁₋₆

alkylNR18COR19, C₁₋₆alky1NR20CONR18R19, NR20CONR18R19, C₁₋₆alky1NR18SO₂R19, NR18SO₂R19;

R18, R19 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C₁₋₄alkyl;

(b) a pharmaceutically acceptable diluent,

wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.